Case Report

Serum iron level in patients with COVID-19: a case report study

Rasoul Alipour¹*, Seyed Hasan Hashemi², Fariba Mikaeili³

¹Department of Emergency Medicine, Emergency Unit of Alinasab Hospital, Social Security Organisation, Treatment Management of East Azerbaijan, Tabriz, Iran
²Department of Gastroenterology, Gastroenterology unit of Alinasab Hospital, Social Security Organisation, Treatment Management of East Azerbaijan, Tabriz, Iran
³Department of Midwifery, Islamic Azad University, Tabriz, Iran

Received: 15 May 2020
Accepted: 08 June 2020

*Correspondence:
Dr. Rasoul Alipour,
E-mail: Dr.Rasoul.Alipour@gmail.com

ABSTRACT

Coronavirus disease emerged in Wuhan, China in December 2019 and led to worldwide pandemic in March 2020. Due to early diagnose, treatment and prevent transmission of COVID-19 disease, we need rapid laboratory tests and develop them. This paper focuses on serum Iron level in patients with COVID-19. We assess the serum Iron level due to the following reasons: I. Iron is a key part of hemoglobin structure in which is essential for providing Oxygen to the body organs, particularly for the patients with pulmonary involvement such as COVID-19. II. Iron deficiency can contribute to muscle weakness and reduction of respiratory capacity, at which increases the risk of deterioration of COVID-19 patients. III. Elevation in Hepcidin level (due to the increase in IL-6 level) in COVID-19 patients inhibits Iron absorption from intestinal lumen and blocks the Iron release from macrophages. IV. Iron is an essential element in infectious suppress and inflammatory process. We noticed that most of the patients, especially admitted to hospital due to the respiratory symptoms, have lower serum Iron level.

Keywords: Coronavirus, COVID-19, Ferritin, Hepcidin, Serum iron level

INTRODUCTION

Coronavirus and COVID-19

The Coronavirus disease, also known as COVID-19, first emerged in Wuhan, China in December 2019.¹ with severe lung diseases and the corresponding virus was named as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in January 2020.² The primary source of COVID-19 is reported to be Rhinolophus bats while the intermediate source is not known.³,⁴ However, the human to human transmission is very fast, which led to worldwide pandemic announcement by WHO in March 2020.⁵ COVID-19 is mostly similar to SARS and MERS, but with more spreading capabilities and severe/deadly forms that exhibits lung injuries in varying stages, such as acute fibrinous, diffuse alveolar damage and pneumonia.⁶,⁷ It has many symptoms including sore throat, nasal congestion, rhinorrhea, fever, cough, fatigue, pneumonia, shortness of breath, myalgia, anorexia, headache, diarrhea, hemoptysis and dyspnea.⁸,⁹

However, patients with COVID-19 are generally asymptomatic and usually have mild disease but it may progress to multi organ dysfunction, particularly in elder patients and those with comorbidities such as Diabetes, Hepatitis, Hypertension, Ischemic Heart Disease and Chronic Renal Disease.⁴,⁸,⁹,10 Children appear to have less severe disease in comparison to adults and almost 90% of
pediatric patients are recognized asymptomatic or with a mild to moderate disease.5,11,12

SARS-CoV-2 remains viable for hours in aerosols and days on many surfaces.13 The SARS-CoV-2 transmission is done by contacting or inhaling infected droplets and the human to human transmit may happen throughout the first few days after the onset of symptoms in symptomatic patients and within initial days of disease in asymptomatic patients.4,9,13 The incubation period of COVID-19 is 5.1 days ranging from 2 to 14 days.4,9 The approval process for vaccine production through various methods is being reviewed and under Confirmation.14 The SARS-CoV-2 must bind with ACE2 receptor to be able to enter the host cells in human body, particularly in alveolar epithelial cells.7,15 Hence, it is necessary to release and express ACE2 to have target organs be infected by SARS-CoV-2 infection.7,15 At the time of this study about 3,181,642 patients and approximately 224,301 deaths were reported for this disease.16 Rapid laboratory testing of SARS-CoV-2 is essential to achieve early diagnose, reporting, quarantine and treatment of patients in which will lead to prevent disease transmission.17 Laboratory findings such as lymphocyte count and inflammatory indices including LDH, CRP and IL-6 may help to diagnose the patients.18 Studies demonstrates that Computed Tomography has a high sensitivity and specificity in the diagnosis of COVID-19 and shows multiple patchy areas of ground glass opacity, consolidation predominately in the periphery of the lungs, adjacent pleura thickening, interlobular septal thickening and air bronchograms.19-21

**Anemia and iron deficiency**

Anemia is diagnosed by a reduction in hemoglobin absolute value or red blood cells count.22 Anemia is identified by Hb level below 13.0 g/dl, 12.0 g/dl. and 11.0 g/dl. in male adults, female adults and pregnant women, respectively.23 However, its level may vary based on age and race criteria.24 It shows to be high levels of Hb in smokers and resident of higher altitudes.25 Anemia can occur at all stages of life cycle, but exhibits more outbreaks in elders, pregnant women and young children.26,27 Anemia has many causes but the most important reason is iron deficiency.26

Iron is an essential element required for many metabolic functions.22 Iron deficiency is the most common reason of anemia and may occur as a result of low iron intake and absorption or increased iron demand or loss.26,28 Iron deficiency can increase the risk of mortality in some diseases such as Chronic Heart failure due to the reduces in Hb status.29

**CASE REPORT**

According to the following 4 reasons, we mentioned that, it is strongly suggested to investigate the serum iron level in patients with COVID-19:

- Patients with COVID-19 may present with respiratory dysfunctions including pneumonia, dyspnea, respiratory distress and acute respiratory distress syndrome (ARDS). These complications reduce blood O2 saturation, and may damage vital organs due to hypoxemia.1-3,5,9,10 Therefore, RBCs and Hb, play an important role in determining the prognosis of these patients. In other words, any defects, dysfunction and decrease in performance (operation) and levels of RBCs and Hb, such as anemia and Iron deficiency, may increase the mortality and organ failure.29-30

- Previous retrospective studies indicated that Inflammatory cytokines, including interleukin-6, interleukin-10 and interleukin-1β were significantly elevated in COVID-19 patients and completely related to severity and fatality of COVID-19.31-36 Furthermore, based on other studies, IL-6 directly regulates hepcidin and increases hepcidin’s level in both acute and chronic inflammation.37-40 Hepcidin is an antimicrobial peptide hormone, secreted by hepatocytes that blocks the iron releasing from macrophages and inhibit absorption of iron from intestinal lumen.37-39,41 So, as a result of hepcidin elevation due to IL-6 elevation in covid-19 patients, serum Iron level may decrease significantly.

- Iron deficiency is related with weakness of skeletal muscles and may decrease respiratory capacity. As a result of respiratory capacity reduction, may induce the deterioration and mortality of patients with COVID-19.42-44

- Various studies show that, Iron has an essential role in suppression of infectious and inflammatory response and may reduce in febrile and autoimmune disease.45-51 However, it is reported to be deposed in some viral and inflammatory diseases.52,53

**METHODS**

In this study, we have selected patients without underlying hematologic disorders who were referred to Alnasab Hospital and diagnosed with COVID-19. Our diagnosis is performed according to the laboratory and radiological criteria including absolute lymphopenia and involved Chest computed tomography. The patients are divided into 3 main categories based on the severity of their respiratory symptoms and need for respiratory support.

- Patients with COVID-19 who have severe respiratory symptoms and are admitted to the ICU due to the need for respiratory support.

- Patients with COVID-19 who have mild respiratory symptoms and are admitted to the Department of Infectious Diseases without the need for respiratory support.

- Patients with COVID-19 without significant respiratory symptoms that are treated on an outpatient basis and sent to quarantine with no need for hospitalization.
Due to our study’s purpose, we proceeded to check serum Iron level randomly for 6 patients selected from each group (in total 18 patients) with different sexes and ages who were referred to Alinasab Hospital at a time point. The data were collected in April 2020. About of 3 ml of the venous blood was extracted from the all samples. After the centrifuging, the separated serum was placed in Mindray BS 800 chemistry analyzer in Alinasab hospital’s laboratory. According to our laboratory reference, the normal conventional range for serum iron level is 65-175 mcg/dL for males and 50-170 mcg/dL for females.54

**DISCUSSION**

Authors found that serum iron levels were lower than normal range in admitted patients and in the patients without apparent respiratory symptoms who referred to quarantine, the serum Iron levels were in the lower limit of normal range (Table 1). Moreover, serum Iron levels in ICU admitted patients were significantly lower than the others.

**Table 1: Table of patients divided by sex, age, place of treatment and serum iron level.**

| Patient no. | Subgroup                        | Sex | Age | Serum iron |
|-------------|---------------------------------|-----|-----|------------|
| 1           | ICU admitted                     | F   | 76  | 27         |
| 2           | ICU admitted                     | M   | 63  | 18         |
| 3           | ICU admitted                     | M   | 80  | 38         |
| 4           | ICU admitted                     | F   | 85  | 20         |
| 5           | ICU admitted                     | F   | 71  | 22         |
| 6           | ICU admitted                     | M   | 68  | 26         |
| 7           | Infectious diseases department   | F   | 59  | 30         |
| 8           | Infectious diseases department   | M   | 62  | 47         |
| 9           | Infectious diseases department   | F   | 67  | 33         |
| 10          | Infectious diseases department   | F   | 79  | 32         |
| 11          | Infectious diseases department t | M   | 82  | 42         |
| 12          | Infectious diseases department t | M   | 54  | 49         |
| 13          | Outpatient clinic                | F   | 76  | 45         |
| 14          | Outpatient clinic                | M   | 59  | 60         |
| 15          | Outpatient clinic                | M   | 54  | 66         |
| 16          | Outpatient clinic                | F   | 78  | 47         |
| 17          | Outpatient clinic                | F   | 57  | 50         |
| 18          | Outpatient clinic                | M   | 81  | 69         |

Based on the results obtained, it can be an inverse communication between serum Iron and the severity of respiratory symptoms (Table 1).

- Due to the high prevalence of iron deficiency in different societies, control and treat of Iron deficiency can be an important factor in preventing the exacerbation of respiratory symptoms in COVID-19 disease.
- Prescribing iron in the acute phase of the disease can be helpful and needs more investigation.
- Iron deficiency in these patients can indicate Iron deposition in various organs that requires further investigation.

**Funding:** No funding sources  
**Conflict of interest:** None declared  
**Ethical approval:** Not required  

**REFERENCES**

1. Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):29.

2. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91-8.

3. Gabutti G, d’Ancheria E, Sandri F, Savio M, Stefanati A. Coronavirus: Update Related to the Current Outbreak of COVID-19. Infect Dis Ther. 2020;8:1-13.

4. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020;87(4):281-6.

5. Tezer H, Bedir Demirdaş T. Novel coronavirus disease (COVID-19) in children. Turk J Med Sci. 2020;592-603.

6. Pambuccian SE. The COVID-19 pandemic: implications for the cytology laboratory. J Am Soc Cytopathol. 2020;9(3):202-11.

7. Rico-Mesa JS, White A, Anderson AS. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. Curr Cardiol Rep. 2020;14:22(5):31.

8. Ozma MA, Maroufi P, Khodadadi E, Köse Ş, Esposito I, Ganbarov K et al. Clinical manifestation, diagnosis, prevention and control of SARS-CoV-2 (COVID-19) during the outbreak period. Infecz Med. 2020;1;28(2):153-65.

9. Park SE. Epidemiology, virology, and clinical features of severe acute respiratory syndrome - coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19). Clin Exp Pediatr. 2020;63(4):119-24.

10. Shahid Z, Kalayaniemitha R, McClafferty B, Kepko D, Ramgobin D, Patel R et al. COVID-19 and older adults: what we know. J Am Geriatr Soc. 2020 May;68(5):926-9.

11. Hasan A, Mehmood N, Fergie J. Coronavirus Disease (COVID-19) and Pediatric Patients: A
23. Review of Epidemiology, Symptomatology, Laboratory and Imaging Results to Guide the Development of a Management Algorithm. Cureus. 2020;12(3):e7485.
12. Choi SH, Kim HW, Kang JM, Kim DH, Cho EY. Epidemiology and clinical features of coronavirus disease 2019 in children. Clin Exp Pediatr. 2020;63(4):125-32.

13. Nikolich-Zugich J, Knox KS, Rios CT, Natt B, Bhattacharya D, Fain MJ. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. Geroscience. 2020;42(2):505-14.

14. Hufert F, Spiegel M. Coronavirus: from common cold to severe pulmonary failure. Monatsschr Kinderheilkd. 2020;1:1-11.

15. Li Y, Zhou W, Yang L, You R. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. Pharmacol Res. 2020;14:104833.

16. World Health Organization. Coronavirus disease 2019, available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed April 2020.

17. Yan Y, Chang L, Wang L. Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): Current status, challenges, and countermeasures. Rev Med Virol. 2020 May;30(3):e2106.

18. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, Psaltopoulos T, Gerotziakas G, Dimopoulos MA. Hematological findings and complications of COVID-19. Am J Hematol. 2020 Apr 13.

19. Rapits CA, Hammer MM, Short RG, Shah A, Bhalla S, Bierhals AJ, et al. Chest CT and Coronavirus Disease (COVID-19): A Critical Review of the Literature to Date. AJR Am J Roentgenol. 2020 Mar 26;1-4.

20. Yang W, Sirajuddin A, Zhang X, Liu G, Teng Z, Zhao S. et al. The role of imaging in 2019 novel coronavirus pneumonia (COVID-19). Eur Radiol. 2020 Apr 15:1-9.

21. Bao C, Liu X, Zhang H, Li Y, Liu J. Coronavirus Disease 2019 (COVID-19) CT Findings: A Systematic Review and Meta-analysis. J Am Coll Radiol. 2020 Mar 25, pii: S1546-1440(20)30262-3.

22. Johnson-Wimbley TD, Graham DY. Diagnosis and management of iron deficiency anemia in the 21st century. Therap Adv Gastroenterol.2011;4(3):177-84.

23. Assessing the Iron Status of Populations. 2nd ed. Geneva, Switzerland: World Health Organization; 2007.

24. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood. 2006;107(5):1747-50.

25. Jimenez K, Kulnigg-Dabisch S, Gasche C. Management of Iron Deficiency Anemia. Gastroenterol Hepatol (NY). 2015;11(4):241-50.

26. Worldwide Prevalence of Anaemia 1993–2005. Bruno de Benoist World Health Organization Geneva, Switzerland.

27. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained. Blood. 2004;104(8):2263-8.

28. Short MW. Iron Deficiency Anemia: Evaluation and Management. Am Fam Physician. 2013; 15;87(2):98-104.

29. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575-82.

30. Hemauer S, Kingerer AJ, Han X, Shotwell MS, Pandharipande PP, Weavind LM. Daily Lowest Hemoglobin and Risk of Organ Dysfunctions in Critically Ill Patients. Crit Care Med. 2017;45(5):479-84.

31. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable serum SARS-CoV-2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin Infect Dis. 2020 Apr 17. pii: ciaa449.

32. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 2020 Apr 10:102452.

33. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020;19(6):102537.

34. Ulhaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 progression. Médicine et Maladies Infectieuses. 2020 Apr 4.

35. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrobial Agents. 2020 Mar 29:105954.

36. Henry BM, De Oliveira MH, Benoît S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. (CCLM). 2020 Jun 25;58(7):1021-8.

37. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108(9):3204-9.

38. McCrnor BJ, Langdon JM, Prince OD, Fennou LK, Berger AE, Cheadle C. Investigation of the role of interleukin-6 and hepcidin antimicrobial peptide in the development of anemia with age. Haematol. 2013;98(10):1633-40.
39. Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica. 2020;105(2):260-72.

40. Yacoub MF, Ferwiz HF, Said F. Effect of Interleukin and Hepcidin in Anemia of Chronic Diseases. Anemia. 2020;6:1-5.

41. Rodriguez R, Jung CL, Gabayan V, Deng JC, Ganz T, Nemeth E, et al. Hepcidin Induction by Pathogens and Pathogen-Derived Molecules Is Strongly Dependent on Interleukin-6. Infect Immun. 2014;82(2):745-52.

42. Leermakers PA, Remels AHV, Zonneveld MI, Rouschop KMA, Schols AMWJ, Gosker HR. Iron deficiency-induced loss of skeletal muscle mitochondrial proteins and respiratory capacity; the role of mitophagy and secretion of mitochondria-containing vesicles. FASEB J. 2020;34:6703-17.

43. Melenovsky V, Hlavata K, Sedivy P, Dezortova M, Borlaug BA, Petrak J, et al. Skeletal Muscle Abnormalities and Iron Deficiency in Chronic Heart Failure. Heart Failure. 2018;11: e004800.

44. Stugiewicz M, Tkaczyszyn M, Kasztura M, Banasiak W, Ponikowski P, Jankowska EA. The influence of iron deficiency on the functioning of skeletal muscles: experimental evidence and clinical implications. Eur J Heart Fail. 2016;18(7):762-73.

45. Wessling-Resnick M. Iron homeostasis and the inflammatory response. Annu Rev Nutr. 2010;30:105-22.

46. Cheryiyl BJ. The role of iron in the immune response to bacterial infection. Immunol Res. 2011;50(1):1-9.

47. Schaible UE, Kaufmann SHE. Iron and microbial infection. Nature Reviews Microbiol. 2004;2:946-53.

48. Ganz T, Nemeth E. Iron sequestration and anemia of inflammation. Semin Hematol. 2009;46:387-93.

49. Eskeland B, Baerheim A, Ulvik R, Hunskaar S. Influence of mild infections on iron status parameters in women of reproductive age. J Pri Health Care. 2009;20:50-6.

50. Dagg JH, Glodberg A, Anderson JR, Beck JS, Gray KG. Autoimmunity in Iron-deficiency Anaemia. Br Med J. 1964;1(5394):1349-50.

51. Hershko C, Hoffbrand AV, Keret D, Souroujon M, Maschler I, Monselise Y, et al. A Role of Autoimmune Gastritis, Helicobacter Pylori and Celiac Disease in Refractory or Unexplained Iron Deficiency Anemia. Haematologica. 2005;90:585-95.

52. Zivadinov R, Weinstock-Guttman B, Pirko I. Iron deposition and inflammation in multiple sclerosis. Which one comes first?. BMC Neurosci. 2011 Dec;12(1):60.

53. Ketonen L, Kieburzt K, Kazee AM, Tuite M. Putaminal Iron Deposition in HIV Infection. J Neuro-AIDS. 1996;1(2):33-40.

54. Hale A, Tradewell GM. NCLEX-PN Notes: course review and exam prep. FA Davis Company. 2010.